Attometrics Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $25K
Latest Deal Amount
  • Investors
  • 1

Attometrics General Information


Developer of a technology designed to detect protein, metabolite and DNA analytes. The company's technology provides rapid screening for infection by E. coli O157:H7 and other bacterial strains that produce deadly Shiga toxin proteins, enabling physicians for detecting biomarkers to identify potential cancers and infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Diagnostic Equipment
Primary Office
  • 15013 South
  • 24th Way
  • Phoenix, AZ 85048
  • United States
+1 (480) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Attometrics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 19-Nov-2012 $25K 0000 Completed Startup
To view Attometrics’s complete valuation and funding history, request access »

Attometrics Executive Team (1)

Name Title Board Seat Contact Info
Wayne Frasch Founder & Chief Executive Officer
To view Attometrics’s complete executive team members history, request access »

Attometrics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ASU Venture Catalyst Accelerator/Incubator Minority 000 0000 000000 0
To view Attometrics’s complete investors history, request access »